Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread

Marinari, Eliana; Dutoit, Valérie; Nikolaev, Sergey I.; Vargas, Maria Isabel; Schaller, Karl; Lobrinus, Johannes Alexander; Dietrich, Pierre‐Yves; Tsantoulis, Petros; Migliorini, Denis

doi:10.1212/nxg.0000000000000561

Cited by 2 publications

(2 citation statements)

References 21 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CAPG participating in immune escape was identified as a poor prognostic gene for LGG patients, of which its higher expression was found in tumor tissues versus that in normal tissues [ 31 , 32 , 33 ]. FLNA was a novel driver gene of tumor metastasis in GBM, and EIF3D was a protective gene for gliomas, of which high expression of EIF3D was related to an improved OS [ 34 , 35 ]. A nomogram analysis displayed that our signature accounted for higher predictive value than other clinical features.…”

Section: Discussionmentioning

confidence: 99%

Development of a Hallmark Pathway-Related Gene Signature Associated with Immune Response for Lower Grade Gliomas

Lai

Zhong

Liu

et al. 2022

IJMS

View full text Add to dashboard Cite

Although some biomarkers have been used to predict prognosis of lower-grade gliomas (LGGs), a pathway-related signature associated with immune response has not been developed. A key signaling pathway was determined according to the lowest adjusted p value among 50 hallmark pathways. The least absolute shrinkage and selection operator (LASSO) and stepwise multivariate Cox analyses were performed to construct a pathway-related gene signature. Somatic mutation, drug sensitivity and prediction of immunotherapy analyses were conducted to reveal the value of this signature in targeted therapies. In this study, an allograft rejection (AR) pathway was considered as a crucial signaling pathway, and we constructed an AR-related five-gene signature, which can independently predict the prognosis of LGGs. High-AR LGG patients had higher tumor mutation burden (TMB), Immunophenscore (IPS), IMmuno-PREdictive Score (IMPRES), T cell-inflamed gene expression profile (GEP) score and MHC I association immunoscore (MIAS) than low-AR patients. Most importantly, our signature can be validated in four immunotherapy cohorts. Furthermore, IC50 values of the six classic chemotherapeutic drugs were significantly elevated in the low-AR group compared with the high-AR group. This signature might be regarded as an underlying biomarker in predicting prognosis for LGGs, possibly providing more therapeutic strategies for future clinical research.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a Hallmark Pathway-Related Gene Signature Associated with Immune Response for Lower Grade Gliomas

Lai

Zhong

Liu

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Limited investigations evaluating genetic alterations in metastatic glioblastoma show that TP53 , TERT , PTEN and RB1 mutations are frequent alterations in metastatic glioblastoma [ 22 , 48 ]. Gain of chromosome 7 with loss of chromosome 10 has also been reported in metastatic glioblastoma [ 68 , 69 ]. Our patient's metastatic tumor carried alterations in TP53 , TERT , PTEN and +7/-10, which were retained among her initial intracranial, recurrent intracranial and metastatic lung tumors ( Figure 3 ).…”

Section: Discussionmentioning

confidence: 99%